C-Reactive Protein as a Novel Biomarker
Document Type
Review
Publication Date
12-1-2004
Description
CRP represents a novel and evolving biomarker for the extent and severity of atherosclerotic lesions and provides a useful predictive indicator for subsequent events. Based on previous studies, increased CRP levels in patients at high risk of cardiovascular disease without documented CAD warrant treatment with statins even if LDL-C levels are within the target range. Patients with documented CAD and high CRP levels should be fallowed closely, and their risk factors should be managed aggressively. Currently, there is no consensus abot the role of CRP levels in monitoring CAD. Formal guidelines about the use of CRP as an independent risk factor and in the day-to-day management of CAD are not yet avaiable despite clear evidence of its usefulness in association with other tools, including the stress test.
Citation Information
Elgharib, Nader; Chi, David S.; Younis, Walid; Wehbe, Salim; and Krishnaswamy, Guha. 2004. C-Reactive Protein as a Novel Biomarker. SENDROM. Vol.16(12). 33-38.